Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gudrun
Gudrun Aldrian-Herrada, Prades-Ie-Lez FR
| Patent application number | Description | Published |
|---|---|---|
| 20090292003 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX | 11-26-2009 |
Gudrun Aldrian-Herrada, Prades-Le-Lez FR
| Patent application number | Description | Published |
|---|---|---|
| 20090156503 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX | 06-18-2009 |
| 20100099626 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX | 04-22-2010 |
Gudrun Claus-Herz, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20080260859 | Composition Containing Omega-3 Fatty Acids and Omega-6 Fatty Acids - A composition comprises at least an omega-3 fatty acid, at least an omega-6 fatty acid, and zinc. The composition is advantageously administered to a subject suffering from a condition of dry eye. In certain embodiment, the amount of omega-3 fatty acid is much higher than that of the omega-6 fatty acid. | 10-23-2008 |
Gudrun Groegor, Reichenau DE
| Patent application number | Description | Published |
|---|---|---|
| 20100183550 | Benzothienopyridines For Use As Inhibitors Of EG5 Kinesin - Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity. | 07-22-2010 |
Gudrun Hofmann, Rheinstetten DE
| Patent application number | Description | Published |
|---|---|---|
| 20100236943 | Method and device for the preparation of liquid samples in NMR spectroscopy using a combined titration and pH electrode - A method and device have an electrode rod ( | 09-23-2010 |
Gudrun Kissinger, Lebus DE
| Patent application number | Description | Published |
|---|---|---|
| 20080311342 | Silicon wafer having good intrinsic getterability and method for its production - Silicon wafers in the entire volume of which crystal lattice vacancies are the prevalent point defect type, have a rotationally symmetric region whose width is at least 80% of the wafer radius, crystal lattice vacancy agglomerates of at least 30 nm in a density ≦6·10 | 12-18-2008 |
| 20100059861 | SEMICONDUCTOR WAFER COMPOSED OF MONOCRYSTALLINE SILICON AND METHOD FOR PRODUCING ITo - Semiconductor wafers composed of monocrystalline silicon and doped with nitrogen contain an OSF region and a PV region, wherein the OSF region extends from the center radially toward the edge of the wafer as far as the P | 03-11-2010 |
| 20120039786 | Silicon Wafer and Method For Producing It - Silicon wafers having an oxygen concentration of 5·10 | 02-16-2012 |
Gudrun Lange, Kelkheim DE
| Patent application number | Description | Published |
|---|---|---|
| 20100273664 | Method For The Determination Of Intra- And Intermolecular Interactions In Aqueous Solution - The present invention relates to the determination of intra- or intermolecular interaction between molecules in aqueous solution, said method comprising the steps of: (a) determining the dehydration (ΔG | 10-28-2010 |
| 20110191897 | Plants Tolerant to HPPD Inhibitor Herbicides - The present invention relates to nucleic acid sequences encoding a hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, abbreviated herein as HPPD) obtained from protists belonging to the family Blepharismidae, as well as the proteins encoded thereby, and to a chimeric gene which comprises such nucleic acid sequence, and to the use of such nucleic acid sequences, proteins or chimeric genes for obtaining plants which are tolerant to HPPD inhibitor herbicides. | 08-04-2011 |
| 20110197307 | Plants Tolerant to HPPD Inhibitor Herbicides - The present invention relates to nucleic acid sequences encoding a hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, abbreviated herein as HPPD) obtained from Euryarchaeota belonging to the family Picrophilaceae, as well as the proteins encoded thereby, and to a chimeric gene which comprises such nucleic acid sequence, and to the use of such nucleic acid sequences, proteins or chimeric genes for obtaining plants which are tolerant to HPPD inhibitor herbicides. | 08-11-2011 |
| 20110197308 | Plants Tolerant to HPPD Inhibitor Herbicides - The present invention relates to nucleic acid sequences encoding a hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, abbreviated herein as HPPD) obtained from bacteria belonging to the genus | 08-11-2011 |
| 20110197309 | Plants Tolerant to HPPD Inhibitor Herbicides - The present invention relates to nucleic acid sequences encoding a hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, abbreviated herein as HPPD) obtained from bacteria belonging to the subfamily Synechococcoideae, as well as the proteins encoded thereby, and to a chimeric gene which comprises such nucleic acid sequence, and to the use of such nucleic acid sequences, proteins or chimeric genes for obtaining plants which are tolerant to HPPD inhibitor herbicides. | 08-11-2011 |
| 20110197310 | Plants Tolerant to HPPD Inhibitor Herbicides - The present invention relates to nucleic acid sequences encoding a hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, abbreviated herein as HPPD) obtained from bacteria belonging to the genus | 08-11-2011 |
| 20110263424 | Oxaspirocyclic Spiro-Substituted Tetramic Acid and Tetronic Acid Derivatives - The present invention relates to novel oxaspirocyclic spirophenyl-substituted tetramic acid and tetronic acid derivatives of the formula (I) | 10-27-2011 |
Gudrun Lasskogen, Hvidovre DK
| Patent application number | Description | Published |
|---|---|---|
| 20100105730 | LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE - Liquid formulations of the DL-lactic acid, the glutaric acid, the L-aspartic acid and the glutamic acid salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and their use in the manufacture of a medicament to be used in the treatment of CNS diseases are provided. | 04-29-2010 |
Gudrun Leopoldsberger, Wuerzburg DE
| Patent application number | Description | Published |
|---|---|---|
| 20100288422 | LOW-TEMPERATURE METHOD FOR JOINING GLASS AND THE LIKE FOR OPTICS AND PRECISION MECHANICS - The present invention relates to a method for joining two or more components made of glass, ceramic, and/or glass ceramic, using a soluble glass joining solution having sodium, potassium, and/or lithium ions and/or a silica sol, the joining solution being applied to joint surfaces between the components to be joined and solidified at mild temperatures, the method being either characterized in that the joining solution comprises an additive selected among boric acid, boron compounds from which boric acid can result by hydrolysis, aluminum acetates, aluminum silicate/NH | 11-18-2010 |
Gudrun Muth-Naumann, Wetter DE
| Patent application number | Description | Published |
|---|---|---|
| 20090162871 | Mutants of the factor VII-activating protease and detection methods using specific antibodies - Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified. | 06-25-2009 |
Gudrun Rappold-Hoerbrand, Heidelberg DE
| Patent application number | Description | Published |
|---|---|---|
| 20080293632 | Use of natriuretic peptides for the treatment of stature disorders related to shox gene - The invention relates to the use of natriuretic peptides (ANP or BNP) for the preparation of pharmaceutical compositions for the treatment of short stature in a subject being suspected of having a genetic defect in the human SHOX gene. Further, the invention relates to use of natriuretic peptides in combination with a growth protein and/or a SHOX protein for the preparation of pharmaceutical compositions for the treatment of patients having a SHOX gene disorder. The invention also relates to the use of natriuretic peptides (ANP and BNP) in combination with a SHOX protein for the preparation of pharmaceutical compositions for the treatment of patients with cardiovascular diseases. The invention also comprises an article of manufacture comprising packaging material and a pharmaceutical composition comprising natriuretic peptides. | 11-27-2008 |
| 20090111744 | Human Growth Gene and Short Stature Gene Region - Subject of the present invention is an isolated human nucleic acid molecule encoding polypeptides containing a homeobox domain of sixty amino acids having the amino acid sequence of SEQ ID NO: 1 and having regulating activity on human growth. Three novel genes residing within the about 500 kb short stature critical region on the X and Y chromosome were identified. At least one of these genes is responsible for the short stature phenotype. The cDNA corresponding to this gene may be used in diagnostic tools, and to further characterize the molecular basis for the short stature-phenotype. In addition, the identification of the gene product of the gene provides new means and methods for the development of superior therapies for short stature. | 04-30-2009 |
Gudrun Reichenauer, Gerbrunn DE
| Patent application number | Description | Published |
|---|---|---|
| 20120020869 | Microporous and Mesoporous Carbon Xerogel Having a Characteristic Mesopore Size and Precursors Thereof and Also a Process for Producing These and Their Use - The invention relates to a microporous and mesoporous carbon xerogel and organic precursors thereof based on a phenol-formaldehyde xerogel. A characteristic parameter common to carbon xerogels is a peak in the mesopore size distribution determined by the BJH method (Barrett-Joyner-Halenda) from nitrogen absorption measurements at 77 K in the range from 3.5 nm to 4 nm. The production process is characterized firstly by the low starting material costs (use of phenol instead of resorcinol) and secondly by very simple and cost-effective processing; convective drying without solvent exchange instead of supercritical drying or freeze drying. The carbon xerogels and their organic phenol-formaldehyde xerogel precursors have densities of corresponding to a porosity of up to 89%, and the xerogels can also have a relevant mesopore volume. The carbon xerogels obtained from the phenol-formaldehyde xerogels are also microporous. | 01-26-2012 |
Gudrun Schappacher, Graz AT
| Patent application number | Description | Published |
|---|---|---|
| 20080297796 | Method for the wavelength calibration of a spectrometer - The invention concerns methods for the wavelength calibration of spectrometers and in particular secondary spectrometers which achieve considerably better calibration accuracies than the conventional peak search methods especially for spectrometers with a relatively large bandwidth. The methods according to the invention are based on the principle of a stepwise relative shift of corresponding measured-value blocks of a model and calibration spectrum where a correlation value is calculated for each shift step. A shift value is determined for each measured-value block at which the correlation value reaches an optimum. A value pair consisting of a position marker of the measured-value block and the associated shift value is determined for each measured-value block. These value pairs represent the design points for fitting to a suitable assignment function. The coefficients obtained in this manner can be used directly as coefficients of a wavelength assignment or be combined with the coefficients of an existing first wavelength assignment in that they for example replace these coefficients or are offset against the coefficients of an existing first wavelength assignment. | 12-04-2008 |
Gudrun Schiedner, Cologne DE
| Patent application number | Description | Published |
|---|---|---|
| 20120040400 | Novel Permanent Human Cell Line - The present invention relates to a permanent human cell line comprising a nucleic acid sequence for the adenoviral gene functions E1A and E1B and the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Further, the present invention relates to a method for transient expression of recombinant polypeptides and proteins in said permanent human cell line. | 02-16-2012 |
Gudrun Schliecker, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20080258438 | Airbag module for a motor vehicle - An airbag module for a motor vehicle includes an airbag that may be inflated for restraining a person, at least one outlet opening for releasing gas out of the module and originating at least partially from the inflated airbag, and a reservoir containing coolant for cooling the gas released from the module through the outlet opening. The reservoir includes a wall that sealingly encloses the coolant and is opened to bring the coolant into direct contact with the released gas to cool the released gas. | 10-23-2008 |
Gudrun Schmitz-Agheguian, Bernried DE
| Patent application number | Description | Published |
|---|---|---|
| 20090093043 | THERMOSTABLE NUCLEIC ACID POLYMERASE FROM THERMOCOCCUS GORGONARIUS - A purified thermostable enzyme is derived form the thermophilic archaebacterium | 04-09-2009 |
| 20110020898 | Thermostable Nucleic Acid Polymerase From Thermococcus Gorgonarius - A purified thermostable enzyme is derived form the thermophilic archaebacterium | 01-27-2011 |
Gudrun Steppich, Achim DE
| Patent application number | Description | Published |
|---|---|---|
| 20100143561 | PET FOOD AND A PROCESS FOR ITS MANUFACTURE - The present invention relates to pet food with a predetermined concentration of butyric acid, 3-methylbutyric acid and/or salt thereof as well as a process for its manufacture. | 06-10-2010 |
Gudrun Stockmanns, Krefeld DE
| Patent application number | Description | Published |
|---|---|---|
| 20090276162 | SENSOR DEVICE AND SENSOR SYSTEM - The invention relates to a sensor device for fastening to human or animal bodies and to a sensor system comprising a plurality of said sensor devices. The sensor devices each comprise a sensor element and a transmission device for the wireless transmission of sensor signals to a receiving device of the sensor system. Thus, universal usability and particularly the suitability to carry out biopotential measurements preferably with automatic detection of configurations is made possible in that the sensor devices each are provided with a connecting device for the electrical connection to a neighboring sensor device and/or a position detection device for detecting the position relative to the neighboring sensor unit. | 11-05-2009 |
Gudrun Vogtentanz, Santa Clara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090111160 | COMPOSITIONS COMPRISING BOWMAN-BIRK PROTEASE INHIBITORS AND VARIANTS THEREOF - The present invention provides compositions and methods related to expression of protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the protease inhibitors. | 04-30-2009 |
| 20100092409 | PERSONAL CARE COMPOSITIONS COMPRISING MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS - The present invention relates to compositions that comprise modified variant Bowman Birk Protease Inhibitor proteins (BBPIs). The modified variant BBPIs comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses the compositions comprising the modified variant BBPIs, and the methods for making and using the compositions in personal care. | 04-15-2010 |
| 20100093028 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS - The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care. | 04-15-2010 |
Gudrun Vogtentanz, Leiden NL
| Patent application number | Description | Published |
|---|---|---|
| 20100221780 | Modified Variant Bowman Birk Protease Inhibitors - The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care. | 09-02-2010 |
| 20110256608 | Modified Variant Bowman Birk Protease Inhibitors - The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care. | 10-20-2011 |
| 20120014885 | Personal Care Compositions and Methods for Their Use - The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments, the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. In alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI. | 01-19-2012 |
Gudrun Vogtentanz, Sunnyvale, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120135500 | CELLULASE VARIANTS WITH IMPROVED EXPRESSION, ACTIVITY AND STABILITY, AND USE THEREOF - The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof. | 05-31-2012 |